Nutri Band Inc. NTRB
We take great care to ensure that the data presented and summarized in this overview for NutriBand Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NTRB
View all-
Vanguard Group Inc Valley Forge, PA125KShares$887,0800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA62.4KShares$444,5370.0% of portfolio
-
State Street Corp Boston, MA17.3KShares$122,9330.0% of portfolio
-
Avantax Advisory Services, Inc.13.6KShares$97,1660.0% of portfolio
-
Haven Private, LLC Orlando, FL11.6KShares$82,3140.03% of portfolio
-
Ubs Group Ag6.24KShares$44,4350.0% of portfolio
-
Fieldpoint Private Securities, LLC5KShares$35,6000.01% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ4.85KShares$34,5390.0% of portfolio
-
Wells Fargo & Company San Francisco, CA1.85KShares$13,1720.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY1.57KShares$11,1920.0% of portfolio
Latest Institutional Activity in NTRB
Top Purchases
Top Sells
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Insider Transactions at NTRB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2023
|
Serguei Melnik President and Secretary |
SELL
Bona fide gift
|
Direct |
5,000
-0.6%
|
-
|
|
Jun 15
2022
|
Gareth Sheridan CEO |
SELL
Bona fide gift
|
Direct |
10,000
-0.66%
|
-
|
|
May 10
2022
|
Gareth Sheridan CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+0.65%
|
$30,000
$3.8 P/Share
|
|
Feb 24
2022
|
Serguei Melnik President and Secretary |
SELL
Open market or private purchase
|
Direct |
5,000
-0.78%
|
$20,000
$4.03 P/Share
|
|
Feb 06
2022
|
Serguei Melnik President and Secretary |
SELL
Bona fide gift
|
Direct |
10,000
-1.56%
|
-
|